ARROYO, David et al. Hypercalcaemia as a side effect of potassium binding agents. []. , 32, 5, pp.655-658. ISSN 1989-2284.  https://dx.doi.org/10.3265/Nefrologia.pre2012.Jun.11500.

Hypercalcaemia is a potential adverse effect of calcium-containing ion exchange resins, often used in the treatment and prevention of hyperkalaemia in chronic kidney disease (CKD). We describe a series of seven outpatients with moderate CKD (mean glomerular filtration rate estimated with the CKD-EPI formula: 41.29±10.83mL/min/1.73m²), presenting mild hypercalcaemia in relation to the treatment with calcium polystyrene sulfonate. Serum calcium increased a mean of 0.91±0.46mg/dL, with a mean concomitant decrease of serum intact parathormone (iPTH) of 52.24±49.29ng/dL. After treatment withdrawal or dose reduction, we observed a recovery of serum calcium and iPTH values. Treatment with calcium-based potassium binders should be included in the differential diagnosis of hypercalcaemia in patients with moderate CKD.

: Ion exchange resins; Hypercalcaemia; Hyperpotassemia; Polystyrene sulfonate calcium.

        · |     · |     · ( pdf )